Ariel Weinberger, Ph.D.
Dr. Ariel Weinberger is the CEO and Co-Founder of Autonomous. He has led the company since its founding in 2017 and has grown the team to 15 scientists, engineers and business professionals. Ariel and the Autonomous team have raised millions of dollars in non-dilutive capital from leading government agencies to transition Autonomous’ antiviral candidates toward first-in-human clinical trials. Prior to founding Autonomous, Ariel was a Principal Investigator and Wyss Technology Development Fellow at Harvard Medical School. Ariel completed his postdoctoral fellowship at Harvard and received his Ph.D. in Biophysics from the University of California, Berkeley. He is an expert in the fields of microbial evolution and drug resistance, and has been a leading author in major scientific journals, including: Cell, mBio, Trends in Biotechnology, PLoS Computational Biology & Cell Host and Microbe.
Leor Weinberger, Ph.D.
Dr. Leor Weinberger is the co-founder of Autonomous and Chair of its Scientific Advisory Board (SAB). He is the William and Ute Bowes Distinguished Professor at the Gladstone Institutes, Professor of Pharmaceutical Chemistry as well as Biochemistry & Biophysics at the University of California, San Francisco (UCSF), and the Founding Director of the Gladstone Center for Cell Circuitry. Leor is a noted expert on HIV and herpes virology and the leading author of seminal publications in: Cell, Science, Nature Genetics and the Proceedings of National Academies of Sciences (PNAS). He is also a Pew Fellow, a Sloan Foundation Fellow, a winner of the Bill & Melinda Gates Foundation Challenge Prize, and awardee of the NIH Director's: Pioneer, New Innovator Awards and Avante-Garde Awards. He is the inventor of the TIP evolving therapy concept.
Timothy Notton, Ph.D.
Dr. Timothy Notton is Director of Engineering at Autonomous and co-inventor of the TIP approach. He earned his Ph.D. in Bioengineering from the University of California, San Francisco and the University of California, Berkeley, where he engineered the first TIP prototypes to control HIV and Zika. Tim is the inventor of the Deletion Platform to rapidly engineer TIPs against any viral pathogen. For his work, Tim was one of 50 early career scientists recently named a DARPA Riser at DARPA’s D60 60th Anniversary Conference.
Paul Leon, ph.D.
Dr. Paul Leon is Associate Director of Business Development and Senior Scientist at Autonomous. Prior to joining Autonomous, Paul quarterbacked pharmaceutical product launches and advised private biotechnology companies as a Senior Consultant at Navigant Consulting, Inc. He earned his Ph.D. in Biomedical Sciences at the Mount Sinai School of Medicine, where he studied virus-immune interactions and helped develop novel universal vaccine approaches for influenza. Paul has published in leading peer-reviewed journals, including: Proceedings of the National Academy of Sciences (PNAS), Immunity, the Journal of Clinical Investigations, Nature Communications, Cell Host & Microbe, & PLoS Pathogens.